Johanne Silvain1, Michel Zeitouni1, Valeria Paradies2, Huili L Zheng3, Gjin Ndrepepa4, Claudio Cavallini5, Dimitri N Feldman6, Samin K Sharma7, Julinda Mehilli8,9, Sebastiano Gili10, Emanuele Barbato11, Giuseppe Tarantini12, Sze Y Ooi13, Clemens von Birgelen14,15, Allan S Jaffe16,17, Kristian Thygesen18, Gilles Montalescot1, Heerajnarain Bulluck19, Derek J Hausenloy20,21,22,23. 1. Sorbonne Université, ACTION Study Group, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), INSERM UMRS 1166, 47-83 bld de l'Hôpital, 75013 Paris, France. 2. Cardiology Department, Maasstad Hospital, Rotterdam, Netherlands. 3. Health Promotion Board, National Registry of Diseases Office, Singapore, Singapore. 4. Department of Adult Cardiology, Deutsches Herzzentrum München, Technische Universität, Munich, Germany. 5. Division of Cardiology, Ospedale S Maria della Misericordia, Piazzale Meneghini 1, Perugia 06100, Italy. 6. Division of Cardiology, Weill Cornell Medical College, New York, NY, USA. 7. Cardiac Catheterization Laboratory, Cardiovascular Institute, Mount Sinai Hospital, New York, NY, USA. 8. Munich University Clinic, Ludwig-Maximilians University, Munich, Germany. 9. German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany. 10. Centro Cardiologico Monzino, IRCCS, Milan, Italy. 11. Department of Advanced Biomedical Sciences, University of Naples Federico II, Napoli, Italy. 12. Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy. 13. Eastern Heart Clinic, Prince of Wales Hospital, Sydney, NSW, Australia. 14. Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, Netherlands. 15. Department of Health Technology and Services Research, Faculty of Behavioural, Management and Social Sciences, Technical Medical Centre, University of Twente, Enschede, Netherlands. 16. Department of Cardiology, Mayo Clinic, Rochester, MN, USA. 17. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. 18. Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark. 19. Department of Cardiology, Norfolk and Norwich University Hospital, Norwich, UK. 20. The Hatter Cardiovascular Institute, University College London, London, UK. 21. Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore, Singapore, Singapore. 22. National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore. 23. Cardiovascular Research Center, College of Medical and Health Sciences, Asia University, Taichung City, Taiwan.
Abstract
AIMS: The prognostic importance of cardiac procedural myocardial injury and myocardial infarction (MI) in chronic coronary syndrome (CCS) patients undergoing elective percutaneous coronary intervention (PCI) is still debated. METHODS AND RESULTS: We analysed individual data of 9081 patients undergoing elective PCI with normal pre-PCI baseline cardiac troponin (cTn) levels. Multivariate models evaluated the association between post-PCI elevations in cTn and 1-year mortality, while an interval analysis evaluated the impact of the size of the myocardial injury on mortality. Our analysis was performed in the overall population and also according to the type of cTn used [52.0% had high-sensitivity cTn (hs-cTn)]. Procedural myocardial injury, as defined by the Fourth Universal Definition of MI (UDMI) [post-PCI cTn elevation ≥1 × 99th percentile upper reference limit (URL)], occurred in 52.8% of patients and was not associated with 1-year mortality [adj odds ratio (OR), 1.35, 95% confidence interval (CI) (0.84-1.77), P = 0.21]. The association between post-PCI cTn elevation and 1-year mortality was significant starting ≥3 × 99th percentile URL. Major myocardial injury defined by post-PCI ≥5 × 99th percentile URL occurred in 18.2% of patients and was associated with a two-fold increase in the adjusted odds of 1-year mortality [2.29, 95% CI (1.32-3.97), P = 0.004]. In the subset of patients for whom periprocedural evidence of ischaemia was collected (n = 2316), Type 4a MI defined by the Fourth UDMI occurred in 12.7% of patients and was strongly associated with 1-year mortality [adj OR 3.21, 95% CI (1.42-7.27), P = 0.005]. We also present our results according to the type of troponin used (hs-cTn or conventional troponin). CONCLUSION: Our analysis has demonstrated that in CCS patients with normal baseline cTn levels, the post-PCI cTn elevation of ≥5 × 99th percentile URL used to define Type 4a MI is associated with 1-year mortality and could be used to detect 'major' procedural myocardial injury in the absence of procedural complications or evidence of new myocardial ischaemia. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: The prognostic importance of cardiac procedural myocardial injury and myocardial infarction (MI) in chronic coronary syndrome (CCS) patients undergoing elective percutaneous coronary intervention (PCI) is still debated. METHODS AND RESULTS: We analysed individual data of 9081 patients undergoing elective PCI with normal pre-PCI baseline cardiac troponin (cTn) levels. Multivariate models evaluated the association between post-PCI elevations in cTn and 1-year mortality, while an interval analysis evaluated the impact of the size of the myocardial injury on mortality. Our analysis was performed in the overall population and also according to the type of cTn used [52.0% had high-sensitivity cTn (hs-cTn)]. Procedural myocardial injury, as defined by the Fourth Universal Definition of MI (UDMI) [post-PCI cTn elevation ≥1 × 99th percentile upper reference limit (URL)], occurred in 52.8% of patients and was not associated with 1-year mortality [adj odds ratio (OR), 1.35, 95% confidence interval (CI) (0.84-1.77), P = 0.21]. The association between post-PCI cTn elevation and 1-year mortality was significant starting ≥3 × 99th percentile URL. Major myocardial injury defined by post-PCI ≥5 × 99th percentile URL occurred in 18.2% of patients and was associated with a two-fold increase in the adjusted odds of 1-year mortality [2.29, 95% CI (1.32-3.97), P = 0.004]. In the subset of patients for whom periprocedural evidence of ischaemia was collected (n = 2316), Type 4a MI defined by the Fourth UDMI occurred in 12.7% of patients and was strongly associated with 1-year mortality [adj OR 3.21, 95% CI (1.42-7.27), P = 0.005]. We also present our results according to the type of troponin used (hs-cTn or conventional troponin). CONCLUSION: Our analysis has demonstrated that in CCS patients with normal baseline cTn levels, the post-PCI cTn elevation of ≥5 × 99th percentile URL used to define Type 4a MI is associated with 1-year mortality and could be used to detect 'major' procedural myocardial injury in the absence of procedural complications or evidence of new myocardial ischaemia. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Gjin Ndrepepa; Roisin Colleran; Siegmund Braun; Salvatore Cassese; Julia Hieber; Massimiliano Fusaro; Sebastian Kufner; Ilka Ott; Robert A Byrne; Oliver Husser; Christian Hengstenberg; Karl-Ludwig Laugwitz; Heribert Schunkert; Adnan Kastrati Journal: J Am Coll Cardiol Date: 2016-11-29 Impact factor: 24.094
Authors: Hector M Garcia-Garcia; Eugène P McFadden; Clemens von Birgelen; Tessa Rademaker-Havinga; Ernest Spitzer; Neal S Kleiman; David J Cohen; Kevin F Kennedy; Edoardo Camenzind; Laura Mauri; Philippe Gabriel Steg; William Wijns; Sigmund Silber; Gerrit-Anne van Es; Patrick W Serruys; Stephan Windecker; Donald Cutlip; Pascal Vranckx Journal: JACC Cardiovasc Interv Date: 2019-10-14 Impact factor: 11.195
Authors: Luigi Di Serafino; Francesco Borgia; Joren Maeremans; Stylianos A Pyxaras; Bernard De Bruyne; William Wijns; Guy R Heyndrickx; Jo Dens; Carlo Di Mario; Emanuele Barbato Journal: J Invasive Cardiol Date: 2016-03-15 Impact factor: 2.022
Authors: Kevin Liou; Nigel Jepson; Petrina Kellar; Ben Ng; Julia Isbister; Robert Giles; Daniel Friedman; Roger Allan; Antony Lau; Mark Pitney; Sze-Yuan Ooi Journal: Heart Lung Circ Date: 2015-02-02 Impact factor: 2.975
Authors: Annapoorna S Kini; Paul Lee; Jonathan D Marmur; Ajay Agarwal; Mary E Duffy; Michael C Kim; Samin K Sharma Journal: Am J Cardiol Date: 2004-01-01 Impact factor: 2.778
Authors: Issam D Moussa; Lloyd W Klein; Binita Shah; Roxana Mehran; Michael J Mack; Emmanouil S Brilakis; John P Reilly; Gilbert Zoghbi; Elizabeth Holper; Gregg W Stone Journal: J Am Coll Cardiol Date: 2013-10-22 Impact factor: 24.094
Authors: Bernard R Chaitman; Karen P Alexander; Derek D Cyr; Jeffrey S Berger; Harmony R Reynolds; Sripal Bangalore; William E Boden; Renato D Lopes; Marcin Demkow; Gian Piero Perna; Robert K Riezebos; Edward O McFalls; Subhash Banerjee; Akshay Bagai; Gilbert Gosselin; Sean M O'Brien; Frank W Rockhold; David D Waters; Kristian A Thygesen; Gregg W Stone; Harvey D White; David J Maron; Judith S Hochman Journal: Circulation Date: 2020-12-03 Impact factor: 29.690
Authors: Johannes Mair; Allan Jaffe; Bertil Lindahl; Nicholas Mills; Martin Möckel; Louise Cullen; Evangelos Giannitsis; Ola Hammarsten; Kurt Huber; Konstantin Krychtiuk; Christian Mueller; Kristian Thygesen Journal: Biomarkers Date: 2022-05-26 Impact factor: 2.663
Authors: Heerajnarain Bulluck; Valeria Paradies; Emanuele Barbato; Andreas Baumbach; Hans Erik Bøtker; Davide Capodanno; Raffaele De Caterina; Claudio Cavallini; Sean M Davidson; Dmitriy N Feldman; Péter Ferdinandy; Sebastiano Gili; Mariann Gyöngyösi; Vijay Kunadian; Sze-Yuan Ooi; Rosalinda Madonna; Michael Marber; Roxana Mehran; Gjin Ndrepepa; Cinzia Perrino; Stefanie Schüpke; Johanne Silvain; Joost P G Sluijter; Giuseppe Tarantini; Gabor G Toth; Linda W Van Laake; Clemens von Birgelen; Michel Zeitouni; Allan S Jaffe; Kristian Thygesen; Derek J Hausenloy Journal: Eur Heart J Date: 2021-07-15 Impact factor: 29.983